Literature Collection

Magnifying Glass
Collection Insights

12K+

References

11K+

Articles

1600+

Grey Literature

4800+

Opioids & SU

The Literature Collection contains over 11,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More

Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).

Enter Search Term(s)
Year
Sort by
Order
Show
12764 Results
8501
Pharmacist utilization of opioid misuse and abuse interventions: Acceptability among pharmacists and patients in Detox
Type: Web Resource
Authors: Tegan Beechey Riley
Year: 2018
Topic(s):
Grey Literature See topic collection
,
Education & Workforce See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

8503
Pharmacist-social worker interprofessional relations and education in mental health: a scoping review
Type: Journal Article
Authors: P. Boylan, J. Knisley, B. Wiskur, J. Nguyen, K. Lam, J. Hong, J. Caballero
Year: 2024
Topic(s):
Education & Workforce See topic collection
8504
Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse
Type: Journal Article
Authors: J. R. Covvey, M. L. Blakely, R. Singh, A. M. Peckham, K. E. Evoy
Year: 2023
Topic(s):
Opioids & Substance Use See topic collection
,
Education & Workforce See topic collection
8506
Pharmacists who screen and discuss opioid misuse with patients: Future directions for research and practice
Type: Journal Article
Authors: Gerald Cochran, Craig Field, Kenneth Lawson
Year: 2015
Topic(s):
Opioids & Substance Use See topic collection
,
Education & Workforce See topic collection
8507
Pharmacists: On the Front Lines
Type: Government Report
Authors: Centers for Disease Control and Prevention
Year: 2015
Publication Place: Atlanta, GA
Topic(s):
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

8508
Pharmacists' different profiles characterization about opioid substitution treatments
Type: Journal Article
Authors: F. Etcheverrigaray, C. Betaud, F. Feuillet, M. Grall-Bronnec, P. Jolliet, C. Victorri-Vigneau
Year: 2016
Publication Place: France
Topic(s):
Opioids & Substance Use See topic collection
,
Education & Workforce See topic collection
8509
Pharmacists' role and experiences with delivering mental health care within team-based primary care settings during the COVID-19 pandemic
Type: Journal Article
Authors: R. Ashcroft, A. Mathers, A. Gin, S. Lam, C. Donnelly, J. B. Brown, T. Kourgiantakis, K. Mehta, J. Rayner, D. Sur, K. Adamson, A. Kirvan, L. Dolovich
Year: 2024
Topic(s):
Education & Workforce See topic collection
8510
Pharmacists’ nonprescription syringe dispensing perceptions and behaviors: A three-state descriptive analysis
Type: Journal Article
Authors: Nicholas E. Hagemeier, KariLynn Dowling-McClay, Mahnaz Baladezaei, Sabrina J. Curtis, Matthew Spence
Year: 2021
Topic(s):
Education & Workforce See topic collection
,
Opioids & Substance Use See topic collection
8511
Pharmacogenetic educational needs and the role of pharmacogenetics in primary care: a focus group study with multiple perspectives
Type: Journal Article
Authors: M. E. Ferwerda, J. A. Wright, R. M. El Melik, J. J. Swen, E. J. Houwink
Year: 2024
Abstract:

BACKGROUND: Pharmacogenomics (PGx) is a well-established concept of how genes impact medication response, with many studies demonstrating reductions in medication side effects, improved efficacy and cost effectiveness. Despite these benefits, implementation of PGx in daily practice remains limited. Studies on the implementation of PGx in clinical practice have previously found that inadequate knowledge is one of the main barriers. Details regarding specifically which educational needs exist among family medicine clinicians requires further study. OBJECTIVE: The aim of this study was to identify both the perceived role that pharmacogenomics (PGx) could play in primary care practice, the knowledge gaps that family medicine clinicians experience, and the skills they require to use PGx in their daily practice. METHODS: To achieve this aim, the attitudes, knowledge, barriers, skills needed, and preferred educational program were explored in a family medicine clinician focus group study via a semi-structured interview and knowledge quiz. Second, multidisciplinary focus groups provided information on the level of knowledge and necessary skills to use PGx in patient care. After gathering key recorded information from both focus groups, the perceived role pharmacogenomics could possibly play in primary care, the predominant knowledge gaps, and the most appropriate educational program was determined by qualitative analysis. RESULTS: Four themes emerged regarding the PGx educational needs and the role of PGx in family medicine: 1) need for PGx competences, 2) insight into the roles and responsibilities of PGx services, 3) optimization of PGx workflow through artificial intelligence integrated in the electronic health record, and 4) the ethical dilemmas and psychological effects related to PGx. These themes reflect a shift in the role of PGx in family medicine with implications for education. CONCLUSION: The results obtained from this study will help improve the implementation of PGx in daily practice, and consequently, may result in increased utilization of PGx, thereby resulting in improved medication efficacy and reduced side effects.

Topic(s):
Opioids & Substance Use See topic collection
,
HIT & Telehealth See topic collection
8512
Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
Type: Journal Article
Authors: A. S. Saber-Tehrani, R. D. Bruce, F. L. Altice
Year: 2011
Publication Place: England
Abstract: BACKGROUND: Psychiatric comorbidities among opioid-dependent patients are common. Many medications used to treat both conditions are metabolized through complimentary cytochrome P450 isoenzymes. When medication-assisted treatment for opioid dependence is concurrently used with psychotropic medications, problematic pharmacokinetic drug interactions may occur. METHODS: We reviewed relevant English language articles identified through the MedLine, Scopus, and Embase databases from 1950 to December 2009 using the specific generic names of medications and keywords such as pharmacokinetics and drug interactions with buprenorphine, methadone, and naltrexone. Selected references from these articles were reviewed. Additionally, a review was conducted of abstracts and conference proceedings from national and international meetings from 1990 to 2009. A total of 60 studies were identified and reviewed. RESULTS: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone, buprenorphine, or naltrexone and some psychoactive medications. Important pharmacokinetic drug interactions have been demonstrated within each class of medications affecting either methadone and buprenorphine or psychoactive drugs. Few studies, however, have been conducted with naltrexone. CONCLUSIONS: Several interactions between methadone, buprenorphine, or naltrexone and psychoactive medications are described and may have important clinical consequences. To optimize care, clinicians must be alerted to these interactions.
Topic(s):
Opioids & Substance Use See topic collection
8513
Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study
Type: Journal Article
Authors: M. Albayaty, M. Linden, H. Olsson, M. Johnsson, K. Strandgarden, F. Tiberg
Year: 2017
Publication Place: United States
Abstract: INTRODUCTION: CAM2038 q1w (once weekly) and q4w (once monthly) are investigational buprenorphine subcutaneous (SC) formulations based on FluidCrystal((R)) injection depot technology. These two drug products are being developed for opioid dependence treatment, with a target for once-weekly and once-monthly SC dosing. The rationale for developing two products with different dosing frequencies is that treatment strategies/routines, and hence different treatment preferences, can vary between patients, different stages of opioid maintenance treatment, and countries. This study evaluated the pharmacokinetics and safety of buprenorphine and norbuprenorphine following administration of CAM2038 q1w or q4w versus active controls. METHODS: Healthy volunteers were randomized to five treatment groups. All received a single intravenous dose of buprenorphine 600 microg, followed post-washout by a single dose of CAM2038 q4w 96 mg, a single dose of CAM2038 q4w 192 mg, or sublingual buprenorphine 8, 16, or 24 mg daily for 7 days, followed post-washout by a single dose of CAM2038 q4w 64 or 128 mg or four repeated weekly doses of CAM2038 q1w 16 mg. All subjects received daily naltrexone. RESULTS: Eighty-seven subjects were randomized. Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w). CAM2038 q4w showed dose-proportional buprenorphine release, with similar exposure to repeat-dose CAM2038 q1w at comparable monthly dose level. Both CAM2038 formulations showed complete absolute bioavailability of buprenorphine and 5.7- to 7.7-fold greater buprenorphine bioavailability versus sublingual buprenorphine. CAM2038 q1w and q4w were well tolerated; subjects' acceptance was higher for CAM2038 than for sublingual buprenorphine 1 h post-dose. CONCLUSIONS: The pharmacokinetic profiles of CAM2038 q1w and q4w versus sublingual buprenorphine support expected treatment efficacy with once-weekly and once-monthly dosing, respectively. CAM2038 formulations were safe and showed good local tolerability. TRIAL REGISTRATION: ISRCTN24987553. FUNDING: Camurus AB.
Topic(s):
Opioids & Substance Use See topic collection
8514
Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Type: Journal Article
Authors: Douglas Bruce, David E. Moody, Diane Chodkowski, Laurie Andrews, Wenfang B. Fang, Jerdravee Morrison, Theresa L. Parsons, Gerald H. Friedland
Year: 2013
Topic(s):
Opioids & Substance Use See topic collection
8517
Pharmacologic considerations in treating depression: a patient-centered approach
Type: Journal Article
Authors: C. B. Ticknor
Year: 2004
Publication Place: United States
Abstract: OBJECTIVE: To review the tricyclic antidepressants, selective serotonin reuptake inhibitors, and dually acting antidepressants and their economic and treatment implications. SUMMARY: Major depressive disorder.s cost to the U.S. economy is staggering, but the selection of drugs available to treat it has expanded to include drugs that have better side-effect profiles. Regardless, remission rates are high, and, often, patients are not treated aggressively enough. Somatic presentations are more common than previously thought, and pain, in particular, may be associated with depression. Pain and depression are both regulated by serotonin and norepinephine, and several studies suggest that using dual-action antidepressants may be helpful in patients who have an element of pain to their disorder. Titration to an adequate dose of any antidepressant is important, as is sustaining treatment for months to years, depending on the patient.s history. CONCLUSION: Increasingly, the mental health community is realizing that the goal of treatment for patients with major depressive disorder must be sustained remission.
Topic(s):
Medically Unexplained Symptoms See topic collection
8518
Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress Disorder and Co-Occurring Opioid Use Disorders
Type: Government Report
Authors: Substance Abuse and Mental Health Services Administration
Year: 2012
Publication Place: Rockville, MD
Topic(s):
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

8519
Pharmacologic management of bipolar disorder in a medicare advantage population
Type: Journal Article
Authors: H. Huang, J. L. Goren, Y. F. Chan, W. Katon, J. Russo, D. Hogan, J. Unutzer
Year: 2014
Publication Place: England
Topic(s):
Healthcare Disparities See topic collection
,
Healthcare Policy See topic collection